Arbutus Reports Third Quarter 2023 Financial Results and Pro

Multiple data presentations upcoming at AASLD – The Liver Meeting®, including preliminary data from Phase 2a clinical trial combining imdusiran, our RNAi therapeutic, with VTP-300, an HBV...

Related Keywords

Canada , United States , Canadian , William Collier , Barinthus Bio , N Acetylgalactosamine Galnac , Michaelj Mcelhaugh , Lisam Caperelli , Securities Exchange , Company Board Of Directors , Arbutus Biopharma Corporation Nasdaq , Roivant Sciences Ltd , World Health Organization , Liver Meeting , Webcast Today , Biopharma Corporation , American Association , Liver Diseases , Chief Executive Officer , Arbutus Co Founder , Cash Equivalents , Months Ended September , Share Purchase , Open Market Sale , Looking Statements , Securities Act , Securities Exchange Act , Arbutu Annual Report , Arbutu Quarterly Reports , Markets ,